pharmaphorum

DECEMBER 15, 2022

Ofev (nintedanib) has been recommended since 2015 for NHS use in IPF patients who have a forced vital capacity (FVC) value of 50% to 80% of normal, but will now be an option for people with less severe disease, i.e. an FVC of more than 80%.

Pharmacology 105

Pharmacology Doctors Patients Medicine 105

European Pharmaceutical Review

JANUARY 18, 2024

Comparatively, in 2015, GlobalData’s research expected that sales of therapies for Gaucher disease will reach $1.16 billion by 2023, driven by the launch of Merck’s Belsomra and Eisai’s lemborexant (E-2006). Gaucher disease market On the other hand, treatments for Gaucher disease, another key market, is expected to reach $1.3

Marketing 98

Marketing Sales Pharmacology Pharma 98

European Pharmaceutical Review

MARCH 11, 2024

In fact, a study published in 2023 in The Lancet HIV revealed that women and men with HIV at age 40 had an average of 39 and 37 years of life left, respectively – only a few years less than that of the general population – if they started antiretroviral therapy (ART) after 2015. World Health Organization. The Global Health Observatory.

Medicine 98

Medicine Pharmacology Healthcare Healthcare 98

European Pharmaceutical Review

OCTOBER 19, 2022

FDA highlighted that over three quarters of new patents in the Orange Book between 2005 and 2015 were assigned to existing drugs. Patent Protection of Pharmacologically Active Metabolites: Theoretical and Technological Analysis on the Jurisprudence of Four Regions. Method for detecting genotoxic impurities in tenofovir. 2020-02-24.

Food and Drug Administration 96

Food and Drug Administration Pharmaceutical products Pharmaceutical FDA 96

pharmaphorum

JANUARY 16, 2023

Across swathes of primary care, pharmacological innovation has stalled; the last new antihypertensive class was introduced in 2007 and new antibiotics have trickled in at a dangerously slow pace. And all are predominantly prevented or treated with medicines that are decades old.

FDA 98

FDA Healthcare Healthcare Medicine 98

European Pharmaceutical Review

FEBRUARY 14, 2024

Firstly, the pharmacological response to LBPs does not follow traditional pharmacokinetic principles. 2015; 69(1):381–403 5. Despite the recent focus, LBPs of defined compositions are yet to be approved for commercialisation for any target indication. Leveraging Quorum Sensing to Manipulate Microbial Dynamics. 2021; 19:100306 4.

Food and Drug Administration 97

Food and Drug Administration Manufacturing Engineering Pharmacology 97

Pharmaceutical Technology

OCTOBER 10, 2022

In 2015, the FDA approved Sprout Pharmaceuticals’s Addyi, also known under the generic name flibanserin, for use by pre-menopausal women with hypoactive sexual desire disorder (HSDD). Moreover, despite the buzz generated when Addyi was launched in 2015, only one other drug has since been marketed.

Pharmacology 59

Pharmacology Side effects FDA Safety 59